Clinical trial

The Effectiveness of Buccal Infiltration Only Using Articaine for Routine Exodontia of Mandibular Molar: A Cross-Over Randomized Controlled Clinical Trial

Name
FPGRP/2023/791/1041
Description
The goal of this clinical trial, is to test out the efficacy of using Articaine only as a local anesthesia as buccal infiltration to extract lower molar teeth. Study will be performed in patients visiting Riyadh Elm University clinics seeking extraction of lower molars bilaterally, in each visit one molar tooth will be extracted using Ariticaine and the second visit with Lidocaine, pain level will be monitored and documented. This study may be helpful in providing scientific information to the oral maxillofacial surgeons which will assist them in choosing the best local anesthetic agent, and possibly substituting using inferior alveolar nerve block with infiltration only when extracting the mandibular posterior teeth.
Trial arms
Trial start
2023-11-30
Estimated PCD
2024-04-10
Trial end
2024-04-30
Status
Not yet recruiting
Phase
Early phase I
Treatment
Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml
4% articaine with 1:100,000 epinephrine buccal infiltration
Arms:
Right mandibular molar
Other names:
Septanest
Lidocaine 2%/Epi 1:100000 Inj Cart 1.7Ml
2% Lidocaine with 1:100,000 epinephrine buccal infiltration
Arms:
Left mandibular molar
Other names:
Octocaine
Size
40
Primary endpoint
Pain measurement
Pain will be measured after injection, during extraction procedure and at the end of the session immediately after finishing the procedure, scale of pain will be 0 for no pain and 10 for maximum pain
Eligibility criteria
Inclusion Criteria: * Male and female patients * Patients with age more than 18 years * Patients indicated for at least one mandibular molar extraction * Patients with the ability to fill the questionnaire Exclusion Criteria: * Patients with abscess or any lesion, which may affect the local anesthesia provision. * Patients with stage III mobile teeth * Patients with a history of medical conditions such as diabetes mellitus, heart disease, pregnancy, allergy or renal disease * Patients who are not able to give an informed consent or are not agreeing to take part in this study
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'interventionModelDescription': 'One 1.8 ml cartridge of 4% articaine with 1:100,000 epinephrine will be utilized in the articaine group and one 1.8 ml cartridge of 2% lidocaine with 1:100,000 epinephrine will be utilized in the lidocaine group. The cartridges will be of similar size and shape, to be allotted a special code, enclosed in thin, adhesive tape by the distributor, and kept into one box for articaine and another box for lidocaine.\n\nA 27-gauge needle will be used for buccal infiltration in each case. Any sensation of pain after administering the local anesthesia will be considered as a failure and an inferior alveolar nerve block will be given. Otherwise, the tooth will be extracted with no additional anesthesia.', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'maskingDescription': 'This is a double blinded randomized clinical trial, which neither the injector (investigator) nor the participant will know what anesthesia type was used in each session.', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}
Updated at
2023-12-08

1 organization

2 products

1 indication

Product
Articaine
Indication
Pain